ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,327Medicare Part D Prescriptions Filled, Including Refills

Rank: 49 out of 434

$440K Total Retail Price of All Prescriptions

Rank: 57 out of 434

698 Patients Receiving at Least One Drug in Part D
65%Patients 65 Years and Older
65% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 698 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

14% of this provider’s 698 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 5,946 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

13 is the average number of prescriptions (including refills) per patient, compared to an average of 13.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
LISINOPRIL 532 374 1 1
LEVOTHYROXINE SODIUM 426 326 2 3
LOVASTATIN 379 246 3 10
METFORMIN HCL 362 247 4 7
HYDROCODONE-ACETAMINOPHEN 346 201 S3 5 4
SIMVASTATIN 330 254 6 2
FUROSEMIDE 239 145 7 9
AMLODIPINE BESYLATE 228 205 8 6
OMEPRAZOLE 225 135 9 5
METOPROLOL TARTRATE 204 138 10 12
RANITIDINE HCL 171 101 11 31
GABAPENTIN 154 95 12 14
ATENOLOL 126 118 13 16
FLUOXETINE HCL 120 36 14 32
TRAZODONE HCL 114 64 15 33
ALENDRONATE SODIUM 114 101 15 15
MELOXICAM 114 85 15 46
LISINOPRIL-HYDROCHLOROTHIAZIDE 113 89 18 21
POTASSIUM CHLORIDE 108 72 19 20
SPIRIVA 108 56 19 36
TRAMADOL HCL 106 60 21 28
HYDROCHLOROTHIAZIDE 102 77 22 8
ZOLPIDEM TARTRATE 93 65 23 11
VENTOLIN HFA 90 46 24 30
ADVAIR DISKUS 90 47 24 52
CITALOPRAM HBR 88 38 26 23
SERTRALINE HCL 85 35 27 27
AMITRIPTYLINE HCL 80 52 R 28 57
CYCLOBENZAPRINE HCL 74 41 R 29 101
FLUTICASONE PROPIONATE 73 33 30 26
RISPERIDONE 67 22 31 87
PROAIR HFA 67 30 31 60
PLAVIX 66 42 33 64
GLIPIZIDE 65 57 34 37
PAROXETINE HCL 59 47 35 61
LOSARTAN POTASSIUM 58 44 36 13
ENALAPRIL MALEATE 57 57 37 59
OXYBUTYNIN CHLORIDE ER 56 34 38 91
PROPRANOLOL HCL 54 30 39 102
KLOR-CON M20 53 17 40 142
LANTUS SOLOSTAR 52 40 41 71
GEMFIBROZIL 50 36 42 62
ACTOS 50 21 42 85
ALLOPURINOL 50 28 42 25
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 18, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.